Inter- and intra-individual comparative study of two gadolinium-based agents: A pilot study

Area of Science:

• Radiology
• Medical Imaging
• Pharmacology

Background:

• Gadolinium-based contrast agents (GBCAs) are essential for MRI.
• Evaluating new GBCAs requires rigorous comparison of safety and efficacy.
• Gadoterate meglumine (Dotarem) and gadobenate dimeglumine (MultiHance) are commonly used GBCAs.

Purpose of the Study:

• To compare the acute adverse event rates and enhancement properties of Dotarem and MultiHance.
• To assess the utility of a controlled, double-blinded study design for evaluating contrast agents.
• To establish a strategy for introducing and re-evaluating contrast agents in clinical practice.

Main Methods:

• A small-scale, controlled, double-blinded study involving 41 patients receiving Dotarem and 46 patients receiving MultiHance (population 1).
• An intra-individual comparison was conducted on 27 patients who received both agents (population 2).
• Adverse events, qualitative, and quantitative image evaluations were statistically analyzed.

Main Results:

• Only one mild adverse event (vomiting) was reported with Dotarem.
• Both agents demonstrated good image quality.
• MultiHance showed significantly higher liver enhancement (p < 0.0001) in population 1.
• Dotarem exhibited a trend towards higher pancreas-to-liver enhancement, significant in population 2 (p = 0.0333).

Conclusions:

• This study provides a robust methodology for evaluating intravenous contrast agents.
• Intra-individual assessment is recommended for optimal evaluation when feasible.
• The findings support the safety and efficacy of both Dotarem and MultiHance, with distinct enhancement profiles.